Cyclophosphamide Drug Interaction Study In Cancer Patients
NCT00334646
Terminated
This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2017
Locations: GSK Investigational Site, Newark, Delaware +4 locations
Conditions: Nausea and Vomiting, Chemotherapy-Induced
Register for Updates
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
NCT00349778
Completed
This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/08/2017
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Multiple Myeloma
Register for Updates
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
NCT00772668
Terminated
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of... Read More
Gender:
ALL
Ages:
Between 17 years and 120 years
Trial Updated:
11/06/2017
Locations: University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida
Conditions: Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates
Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
NCT00278564
Terminated
Myositis is a disease, believed to be due to immune cells, cells which normally protect the body, but are now attacking the muscles and other organ systems within body. As a result, the affected muscles and organs fail to work properly causing weakness, difficulty swallowing, skin rash, respiratory problems, heart problems, joint stiffness, soft tissue calcification and vasculitis (blood circulation problems). The likelihood of progression of this disease is high. This study is designed to exami... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
11/03/2017
Locations: Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Conditions: MYOPATHY
Register for Updates
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
NCT00238368
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy with an autologous stem cell or bone marrow transplant may allow more chemotherapy to be given so that more cancer cells are killed. Procedures, such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) (done during chemotherapy)... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
11/01/2017
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Lymphoma
Register for Updates
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
NCT00258206
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with cyclophosphamide may kill more cancer cells. PURP... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
11/01/2017
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
NCT01740401
Terminated
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer. The investigators expect to see an increase in response rate of the combination over Anti-CTLA-4 alone and estimate a response rate of approximately 20 % in the proposed population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2017
Locations: New York University Langone Clinical Cancer Center, New York, New York
Conditions: Melanoma
Register for Updates
Hematopoietic Stem Cell Support in Vasculitis
NCT00278512
Terminated
The systemic vasculitis is a wide-ranging group of diseases that are characterized by the presence of blood vessel inflammation (1). Despite this common feature, each type of vasculitis has a unique variety of clinical manifestations that influences its degree of disease severity and ultimately its management. Immunosuppressive therapy forms the foundation of treatment for almost all forms of systemic vasculitis. The systemic necrotizing vasculitis (SNV) are a subset of vasculitis with signific... Read More
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
10/30/2017
Locations: Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Conditions: Vasculitis
Register for Updates
Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism
NCT00282412
Terminated
Rheumatoid arthritis disease is believed to be due to immune cells, cells that normally protect the body and are now causing damage to the body. Risk of death is highest in people with twenty or more joints actively involved with disease, positive rheumatoid factor, an elevated sedimentation rate (laboratory measures of active inflammation), and patients with limitation of daily activities (trouble doing simple things like opening a carton of milk). In these high risk patients, life is significa... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/24/2017
Locations: Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Conditions: Rheumatoid Arthritis
Register for Updates
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00425802
Completed
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as rituximab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer ce... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/24/2017
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Leukemia, Lymphoma
Register for Updates
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
NCT01313884
Terminated
The outcome of patients with metastatic Ewings Sarcoma is poor with current standard of care chemotherapy, with less than 30% survival. Based on recent encouraging pediatric literature we have designed this trial to improve the outcome of patients with metastatic Ewings sarcoma using Irinotecan and Temozolomide in addition to standard chemotherapy.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
10/20/2017
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Bone Cancer, Ewing's Sarcoma
Register for Updates
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
NCT00083915
Completed
The purpose of this study is to find out if transplant with a new regimen of chemotherapy called DT PACE-Melphalan is better than transplant with Melphalan alone. DT-PACE refers to a chemotherapy regimen for multiple myeloma consisting of Dexamethasone, Thalidomide, Cisplatin or Platinol, Adriamycin or doxorubicin, Cyclophosphamide, and Etoposide. Another purpose of this study is to find out if there will be fewer side effects with the new regimen of DT PACE-Melphalan, compared to melphalan alon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2017
Locations: University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates